Related Experiment Videos
Norepinephrine dipivalylate dose-response in ocular hypertensive subjects
Annals of Ophthalmology
|November 1, 1981
Summary
Norepinephrine dipivalylate effectively lowered intraocular pressure in ocular hypertensive patients. The 0.5% concentration showed significant, clinically acceptable results with no major side effects.
Area of Science:
- Ophthalmology
- Pharmacology
- Ocular Hypertension
Background:
- Ocular hypertension is a risk factor for glaucoma.
- Norepinephrine dipivalylate is a prodrug analog of norepinephrine.
Purpose of the Study:
- To evaluate the efficacy and safety of norepinephrine dipivalylate in reducing intraocular pressure (IOP).
Main Methods:
- 12 ocular hypertensive patients received single weekly instillations of norepinephrine dipivalylate (0.05%-0.5%) or placebo in one eye.
- IOP, pupil size, ocular signs, symptoms, heart rate, and blood pressure were monitored for 12 hours.
Main Results:
- A dose-response reduction in IOP was observed.
- The 0.5% concentration significantly lowered IOP compared to placebo at 6, 8, and 12 hours.
- No clinically significant side effects were reported.
Conclusions:
- Norepinephrine dipivalylate demonstrates a dose-dependent IOP-lowering effect.
- The 0.5% concentration is effective and well-tolerated for managing ocular hypertension.